# US 2009/0011016 A1 · Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0011016 A1
- Document ID: US20090011016A1
- Status: Published application
- Kind: A1
- Application number: 12/224,385
- Filed: 2007-03-01
- Published: 2009-01-08
- Earliest claimed: 2006-03-01
- Assignees: Ethypharm
- Inventors: Vincent Cailly-Dufestel; Catherine Herry; Johnatan Bacon; Pascal Oury
- Web page: https://patentgrep.com/patent/US20090011016A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.

## Claims

### Claim 1

Water-insoluble, matrix tablets comprising oxycodone or one of its pharmaceutically acceptable salts, capable of releasing oxycodone into the body over an extended time period and comprising oxycodone within a compression matrix, said matrix comprising at least one excipient chosen from the group consisting of sustained-release, pH-independent, water-insoluble polymers, mineral excipients and their mixtures, wherein the quantity of excipient and the compression conditions are chosen so that the crush resistance of said tablets is at least 4 MPa, advantageously at least 6 MPa.

### Claim 2 (depends on 1)

Matrix tablets according to claim 1, wherein neither the mixture to be compressed, nor the compression tooling are subjected to a heating step either before or during the actual compression step.

### Claim 3 (depends on 1)

Matrix tablets according to claim 1, wherein said compression matrix represents 50 to 98 weight % of the total weight of said tablet, advantageously 85 to 95%.

### Claim 4 (depends on 1)

Matrix tablets according to claim 1, wherein said compression matrix comprises a mixture of at least two excipients selected from the group consisting of sustained-release, pH-independent, water-insoluble polymers, mineral excipients and their mixtures.

### Claim 5 (depends on 1)

Matrix tablets according to claim 1, wherein said sustained-release, pH-independent, water-insoluble polymers are selected from the group consisting of cellulose derivatives, water-insoluble methacrylic acids, derivatives of polyvinylalcohols, derivatives of polyvinyl acetates, derivatives of polyvinylpyrrolidone, lactic and glycolic acid polymers, starches, waxes and their mixtures.

### Claim 6 (depends on 1)

Matrix tablets according to claim 1, wherein the mineral excipients are selected from the group consisting of calcium phosphates, aluminium and silicon silicates, magnesium carbonate and their mixtures.

### Claim 7 (depends on 1)

Matrix tablets according to claim 1, wherein said polymers are selected from the group consisting of the mixture of microcrystalline cellulose and [polyvinyl acetate/polyvinylpyrrolidone (80:20)], and the mixture of microcrystalline cellulose and [poly(ethylacrylate/methylmethacrylate/trimethyl-amonioethyl methacrylate chloride) (1:2:0.2)].

### Claim 8 (depends on 1)

Matrix tablets according to claim 1, wherein said compression matrix also comprises at least one pharmaceutically acceptable excipient selected from the group consisting of anti-adherent agents, agents able to improve tablet cohesion on compressing, fillers, lubricants, plasticizers, bulking agents, sweeteners and colouring agents.

### Claim 9 (depends on 1)

Matrix tablets according to claim 1, wherein said compression matrix also comprises at least one or more of the following substances (a) to (f) or a mixture thereof:
a) a substance which irritates the nasal and/or pharyngeal tracts,
b) a viscosity-increasing agent, leading to formation of a gel when the tablet is dissolved in a minimum amount of water,
c) an emetic substance,
d) an aversive colouring agent,
e) a bittering substance,
f) an antagonist of oxycodone.

### Claim 10 (depends on 9)

Matrix tablets according to claim 9, wherein the antagonist agent is naloxone or naltrexone or one of their pharmaceutically acceptable salts.

### Claim 11 (depends on 1)

Matrix tablets according to claim 1, further comprising an outer coating.

### Claim 12 (depends on 11)

Matrix tablets according to claim 11, wherein said outer coating comprises at least one sustained-release polymer advantageously chosen from the group comprising ethylcellulose derivatives and methacrylic polymers.

### Claim 13 (depends on 1)

Matrix tablets according to claim 1, wherein said matrix comprises a mixture of microcrystalline cellulose and [polyvinyl acetate/polyvinylpyrrolidone (80:20)] to the proportion of (1:1).

### Claim 14 (depends on 13)

Matrix tablets according to claim 13, further comprising an outer coating comprising ethylcellulose.

### Claim 15 (depends on 1)

Matrix tablets according to claim 1, wherein said tablets are capable of releasing oxycodone over a period of more than 12 hours.

### Claim 16 (depends on 1)

Matrix tablets according to claim 1, wherein said tablets are capable of releasing oxycodone over a period of more than 20 hours.

### Claim 17 (depends on 13)

Matrix tablets according to claim 13, wherein said tablets have a plasma profile after once-a-day administration in man, such that the ratio of the Cmax observed after administration of said tablets to the Cmax value observed after administration of OxyContin® extended release tablets containing the same dose, does not exceed 0.7.

### Claim 18 (depends on 13)

Matrix tablets containing oxycodone according to claim 13, wherein a plasma profile after once-a-day administration in man is such that the ratio of AUC∞ observed for said tablets to the AUC∞ value observed with OxyContin® extended release tablets with the same dose, lies in the interval of 80 to 125%.

### Claim 19 (depends on 1)

Tablets according to claim 1, suitable for administration once a day.

### Claim 20 (depends on 1)

Method to produce matrix tablets according to claim 1, comprising the following steps:
mixing the active ingredient(s) with the excipient(s) of the compression matrix,
optional granulation, and
compressing said mixture under conditions chosen so that said tablet has a crush resistance of at least 4 MPa, advantageously at least 6 MPa.

### Claim 21 (depends on 20)

Method according to claim 20, wherein the compression step is conducted without the compression mixture or the compression tooling being subjected to a heating step either before or during the actual compression step.

### Claim 22 (depends on 20)

Method according to claim 20, further comprising coating said matrix tablet.

### Claim 23 (depends on 22)

Method according to claim 22, a further comprising curing said outer coating.

### Claim 24 (depends on 1)

A method comprising administering a pharmaceutical composition in the form of tablets according to claim 1, for the sustained delivery of oxycodone, and intended to prevent accidental misuse and/or to deter drug abuse of oxycodone.
